




*Fondazione per la Ricerca  
sulla Fibrosi Cistica - Onlus  
italian cystic fibrosis research foundation*

# 20<sup>th</sup> Convention

of investigators in cystic fibrosis  
24 - 26 November 2022  
Camera di Commercio, Corso Porta Nuova 96 - Verona



## Full program

(oral presentation)

Piazzale Stefani 1 | c/o Azienda Ospedaliera Universitaria Integrata | 37126 Verona  
Codice fiscale 93100600233 | [fondazione.ricercafc@aovr.veneto.it](mailto:fondazione.ricercafc@aovr.veneto.it) | Tel 045 812 3438

[fibrosicisticaricerca.it](http://fibrosicisticaricerca.it)

09:30 - 10:30	Registration and poster display
10:30 - 11:15	Introduction and greetings <b>Matteo Marzotto</b> ( <i>President FFC Ricerca</i> ) <b>Gianna Puppo Fornaro</b> ( <i>President LIFC Lega Italiana Fibrosi Cistica</i> ) <b>Marco Cipolli</b> ( <i>President SIFC Società Italiana Fibrosi Cistica</i> ) <b>Francesco Blasi</b> ( <i>Vice President SIFC Società Italiana Fibrosi Cistica</i> ) <b>Callisto Marco Bravi</b> ( <i>Director AOUI Verona</i> ) <b>Carlo Castellani</b> ( <i>Scientific director FFC Ricerca</i> )
11:15 - 12:05 <b>SESSION 1</b>	<b>GENE EDITING IN CYSTIC FIBROSIS</b> <i>Chair: Francesco Blasi, Giulio Cabrini</i> <ol style="list-style-type: none"><li><b>Giulia Maule</b> (GMSG #1/2022) Development of CRISPR-Cas delivery system for genome editing applications in cystic fibrosis (10')</li><li><b>Anna Cereseto, Daniele Arosio</b> (FFC#2/2021) Harnessing CRISPR-Cas technology to revert F508del CFTR defect (10')</li><li><b>Aldo Di Leonardo</b> (FFC#5/2021) <i>In vitro</i> evaluation of novel sequence-specific RNA editing tools to rescue nonsense mutant CFTR transcript (10')</li></ol>
11:45 - 12:05	Discussion
12:05 - 13:15 <b>SESSION 2</b>	<b>NEW PERSPECTIVES IN CFTR MODULATORS</b> <i>Chair: Francesco Blasi, Tiziano Bandiera</i> <ol style="list-style-type: none"><li><b>Paola Barraja, Arianna Venturini</b> (FFC#3/2020) Small nitrogen heterocycles as correctors of the mutant CFTR protein in cystic fibrosis (15')</li><li><b>Paola Barraja, J.V. Galiotta</b> (Molecole 3.0) New generation of pharmacological modulators to rescue mutant CFTR protein (15')</li><li><b>Fabio Bertozzi</b> (FFC#2/2022, FFC#4/2020) Characterization of CFTR modulators mechanism of action via Photo-Affinity Labeling (PAL) approach (15')</li></ol>
12:55 - 13:15	Discussion
13:15 - 14:50	Lunch (brown-bag) & Poster session
14:50 - 15:40 <b>SESSION 3</b>	<b>CFTR MODULATOR THERAPIES FOR ORPHAN MUTATIONS</b> <i>Chair: Marco Cipolli, Oscar Moran</i> <ol style="list-style-type: none"><li><b>Emilio Hirsch</b> (FFC#3/2022) Rescuing rare CFTR mutants with a PI3K<math>\gamma</math> mimetic peptide (8')</li><li><b>Adriana Chilin, Gergely Lukacs</b> (FFC#3/2021) Toward the development of tailored therapies for insensitive CF gating mutations (10')</li><li><b>Laura Lentini, Ivana Pibiri</b> (FFC#6/2020) Validation of the biodistribution and activity of new optimized leads in mouse model and other CF model systems (10')</li></ol>
15:18 - 15:40	Discussion

15:40 - 17:00  
SESSION 4

## CLINICAL STUDIES

*Chair: Marco Cipolli, Roberto Buzzetti*

10. **Alberto Battezzati, Carla Colombo, Maria Cristina Lucanto, Vincenzina Lucidi, Andrea Mari** (FFC#24/2019)  
Early derangements of glucose tolerance in cystic fibrosis: effect of CFTR modulators (10')
11. **Cesare Braggion, Sonia Volpi** (Effetto Kaftrio)  
Safety and effectiveness of elexacaftor/tezacaftor/ivacaftor (Kaftrio) in patients with cystic fibrosis and advanced lung disease: an Italian observational, multicenter study (10')
12. **Riccardo Percudani, Gianfranco Pasut, Rosaria Casciaro** (FFC#14/2022)  
Actin-resistant acidic DNase for the treatment of CF pulmonary symptoms (8')
13. **Vittorio Scaravilli** (FFC#27/2019)  
Right ventricle dysfunction in cystic fibrosis patients undergoing lung transplantation (10')
14. **Gianluca Serafini, Riccardo Ciprandi** (FFC#21/2021)  
Mental health in cystic fibrosis patients: the prognostic role of temperament, personality and attachment styles (10')

16:28 - 17:00 Discussion

17:00 - 17:30 Coffee Break

17:30 - 18:45  
SESSION 5

## BIOMARKERS AND SCREENING IN CYSTIC FIBROSIS

*Chair: Graziella Borgo, Nicoletta Pedemonte*

15. **Carlo Laudanna** (FFC#7/2021)  
Monocyte integrin activation as a cystic fibrosis drug evaluation test: validation phase (15')
16. **Giovanni Morana** (FFC#26/2019)  
Standardized Ventilation Inflammation Perfusion and Structure (VIPS) MRI platform for monitoring cystic fibrosis lung disease (15')
17. **Vito Terlizzi, Laura Elisabetta Claut, Antonella Tosco** (FFC#24/2020)  
Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): an Italian multicenter survey evaluating prevalence, clinical data, management, and outcome (10')
18. **Carlo Castellani** (1 in 30 and You Don't Know It)  
A platform for a better comprehension of the cystic fibrosis carrier test (10')

18:20 - 18:45 Discussion

08:30 - 09:40  
SESSION 6

## ALTERNATIVE PATHWAYS TO CORRECT CFTR

*Chair: Paola Melotti, Paolo Bernardi*

19. **Giorgio Cozza, Federica Rossin** (FFC#4/2021)  
Oxidative stress and autophagy in cystic fibrosis: novel biochemical characterizations and drug discovery approaches (10')
20. **Luis J. V. Galiotta** (FFC#9/2022)  
Effect of inflammatory stimuli on airway epithelium ion transport in cystic fibrosis (8')
21. **Paolo Scudieri, Fabiana Ciciriello** (FFC#11/2021)  
Alternative targets for the treatment of cystic fibrosis basic defect (10')
22. **Mauro Piacentini, Valeria Raia** (FFC#8/2022, FFC#15/2020)  
Targeting the STING/Transglutaminase 2-regulated Interferon response as a novel host-direct approach to fight bacterial infections in cystic fibrosis (15')

09:13 - 09:40 Discussion

09:40 - 11:05  
SESSION 7

## ANTI-INFLAMMATORY APPROACHES IN CYSTIC FIBROSIS

*Chair: Laura Minicucci, Giulio Cabrini*

23. **Domenico Mattoscio** (FFC#11/2022)  
Targeting platelet activation with pro-resolving mediators: an innovative strategy to dampen lung inflammation in cystic fibrosis (8')
24. **Antonio Recchiuti, Alessandra Aloisi** (FFC#20/2021)  
Nanotechnology-based Resolvin D1 as proresolving therapy in cystic fibrosis: preclinical studies for the delivery of innovative formulations to the clinic (15')
25. **Ilaria Lampronti** (FFC#10/2022)  
Towards the development of GY-971a as anti-inflammatory drug in cystic fibrosis (8')
26. **Vincenzo Summa, Lucia Altucci** (FFC#20/2020)  
Harnessing selective histone deacetylase 6 (HDAC6) inhibition to tackle inflammation and fibrotic remodeling in cystic fibrosis (15')
27. **Stefano Giovagnoli** (FFC#17/2020)  
Oral and pulmonary delivery platforms for anakinra repurposing in cystic fibrosis (15')

10:41 - 11:10 Discussion

11:10 - 11:40 Coffee Break

11:40 - 12:55  
SESSION 8

## STRATEGIES TO CONTRAST ANTIMICROBIAL RESISTANCE

*Chair: Giovanni Taccetti, Maria Luisa Mangoni*

28. **Giovanni Bertoni** (FFC#14/2021)  
Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against *Pseudomonas aeruginosa* (15')
29. **Laurent Robert Chiarelli, Fiorella Meneghetti, Sonia Covaceuszach** (FFC#5/2022)  
Nontuberculous mycobacteria in cystic fibrosis: scouting molecules against *Mycobacterium abscessus* iron acquisition pathways (8')
30. **Federica Briani** (FFC#15/2021)  
Tackling phage resistance to increase the robustness of phage therapy for curing *Pseudomonas aeruginosa* infections in patients with cystic fibrosis (15')

	31. <b>Fiorentina Ascenzioni, Bruno Botta, Mattia Mori, Stefano Salmaso</b> (FFC#12/2021) Pharmacological inhibition of colistin resistance in Gram-negative cystic fibrosis pathogens (10')
	32. <b>Anna Silvia Pistocchi</b> (FFC#12/2022) Evaluation of phage interactions with host immune system in models of cystic fibrosis: one step toward phage therapy application (8')
12:36 - 13:05	Discussion
13:05 - 14:35	Lunch (brown-bag) & Poster session
14:35 - 15:35 <b>SESSION 9</b>	<b>NEW DRUGS AGAINST MYCOBACTERIUM ABSCESSUS</b> <i>Chair: Michele Gangemi, Emilio Clementi</i>
	33. <b>Federico Giannoni, Emanuele Borroni, Lanfranco Fattorini</b> (FFC#6/2022, FFC#17/2021) New drug combinations against non-tuberculous mycobacteria infections in cystic fibrosis (15')
	34. <b>Maria Rosaria Pasca, Vadim Makarov, Santiago Ramón-García, Enrico Tortoli</b> (FFC#18/2021) New weapons against <i>Mycobacterium abscessus</i> and other nontuberculous mycobacteria (15')
	35. <b>Maurizio Fraziano, Daniela Maria Cirillo</b> (FFC#13/2022) Fighting <i>Mycobacterium abscessus</i> infections by a novel combination therapy (8')
	36. <b>Nicola Ivan Lorè, Lisa Cariani</b> (FFC#7/2022, FFC#23/2020) Genomic and phenotypic characterization of <i>Mycobacterium abscessus</i> and detection of host biomarkers to define mycobacterial infection in cystic fibrosis (15')
15:28 - 15:50	Discussion
15:50 - 16:25	Coffee Break
16:25 - 16:55 <b>KEYNOTE SPEECH</b>	<b>Protecting inventions: a brief journey into the world of patents</b> <b>Tiziano Bandiera</b> (30')
16:55 - 17:45 <b>SESSION 10</b>	<b>THERATYPING AND PRIMARY CELLS MODELS</b> <i>Chair: Carlo Castellani, Luis J. V. Galiotta</i>
	37. <b>Onofrio Laselva, Enza Montemitro, Graziano Pesole</b> (FFC#6/2021) Enhancing the prediction of clinical responses to CFTR modulators by <i>in vitro</i> assays using patient-derived tissues under conditions mimicking native status of CF airways (10')
	38. <b>Paola Melotti, Marcel Bijvelds, Giuseppe Castaldo</b> (FFC#9/2020) Theratyping of rare CFTR genotypes for treatment with CFTR modulators (15')
	39. <b>Marco Lucarelli, Adriana Eramo</b> (FFC#8/2021) Theratyping of cystic fibrosis (10')
	40. <b>Nicoletta Pedemonte, Renata Bocciardi</b> (FFC#10/2021) Theratyping orphan mutations in Italian cystic fibrosis patients: meeting unmet needs (10')
17:40 - 18:05	Discussion
20:00	Social Dinner

09:00 - 10:20  
SESSION 11

## ANTI-INFECTIVE STRATEGIES IN CYSTIC FIBROSIS

*Chair: Cesare Braggion, Natalia Cirilli*

41. **Carla Vignaroli, Barbara Citterio, Gianmarco Mangiaterra** (FFC#16/2019)  
Fighting *Pseudomonas aeruginosa* persists in cystic fibrosis pulmonary infections: improved detection and therapeutic strategies (15')
42. **Cristina Cigana, Daniela Girelli, Ersilia Fiscarelli** (FFC#16/2021)  
Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease (10')
43. **Teresa Zelante** (FFC#15/2022)  
Study on anti-fungal immunoglobulins, as a potential diagnostic biomarker and therapeutic values for allergic bronchopulmonary aspergillosis in children with cystic fibrosis (8')
44. **Barbara Cellini** (FFC#19/2021)  
Exploring the dual targeting of host and microbial sphingosine-1-phosphate lyase as antimicrobial strategy in cystic fibrosis (15')
45. **Alessandra Bragonzi, Giacomo Rossi** (FFC#2/2019)  
Bridging airway mucus-microbiota-host genotype to define novel cystic fibrosis models (15')

10:03 - 10:30

Discussion

10:30 - 12:10  
SESSION 12

## TREATMENT OF PULMONARY INFECTION

*Chair: Cesare Braggion, Alessandra Bragonzi*

46. **Natalia Cirilli, Luca Tiano, Rosaria Gesuita** (FFC#22/2020)  
Role of viable but non culturable (VBNC) bacterial forms in CF patients in a clinical setting: a translational research (10')
47. **Moira Paroni, Helle Krogh Johansen** (FFC#18/2020)  
Counteracting inflammation triggered by *Pseudomonas aeruginosa*-activated lung-infiltrating Th1/17 cells: a novel approach for precision medicine in CF (15')
48. **Paolo Visca, Raffaella Sorrentino** (FFC#19/2019)  
Gallium as an antibacterial agent in cystic fibrosis: animal studies for the delivery of inhalable formulations to the clinic (15')
49. **Giovanna Batoni, Arianna Pompilio** (FFC#13/2021)  
Probiotics: an emerging strategy to fight bacterial pulmonary infections in cystic fibrosis (15')
50. **Annalisa Guaragna, Eliana De Gregorio** (FFC#13/2020)  
Can old and new sweet glycomimetics act as antibacterial and antibiofilm agents in the treatment of CF lung disease infections? (15')

11:40 - 12:10

Discussion

12:10 - 12:40

Coffee Break

12:40 - 14:15  
SESSION 13

## PHARMACEUTICAL MODULATORS INTERACTION

*Chair: Graziella Borgo, Oscar Moran*

51. **Andrea Armirotti, Elvira Sondo** (FFC#1/2021)  
Multiomics exploration of the CF primary bronchial epithelium lipidome and its role on CFTR rescue (10')
52. **Massimo Aureli, Anna Tamanini** (FFC#1/2022, FFC#2/2020)  
A lipid-based therapeutic approach to rescue F508del-CFTR and CFTR with orphan mutations and implications in bacterial infections in cystic fibrosis (15')

53. **Enrico Millo, Elena Cichero, Santina Bruzzone** (FFC#9/2021)  
Lead optimization of MKT-077 analogues as Hsp70 allosteric inhibitors combined with F508del CFTR correctors: a multi-drug approach to contrast cystic fibrosis (10')
54. **Felice Amato** (FFC#1/2020)  
Peptide nucleic acids as a promising CFTR potentiator for the treatment of cystic fibrosis (15')
55. **Maria Luisa Mangoni, Arianna Venturini, Mattia Mori** (FFC#4/2022)  
Esculentin-derived peptides as novel therapeutic agents with antimicrobial and CFTR potentiator activities to address cystic fibrosis lung disease (8')

13:38 - 14:10 Discussion

14:10 - 14:20 Closing remarks

14:20 - 15:00 Poster detachment

## Notes

---



---



---



---



---



---



---



---



---



---